Aptevo Therapeutics (NASDAQ:APVO) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Aptevo Therapeutics (NASDAQ:APVO) from a sell rating to a hold rating in a research note released on Sunday.

Separately, Weiss Ratings reaffirmed a “sell (e)” rating on shares of Aptevo Therapeutics in a research report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold”.

Aptevo Therapeutics Price Performance

NASDAQ APVO opened at $4.27 on Friday. Aptevo Therapeutics has a 1 year low of $3.84 and a 1 year high of $1,299.60. The company has a market capitalization of $5.04 million, a PE ratio of 0.00 and a beta of 1.44. The company has a fifty day moving average of $6.31 and a two-hundred day moving average of $16.55.

Aptevo Therapeutics (NASDAQ:APVO) last announced its earnings results on Friday, March 27th. The biotechnology company reported $118.23 earnings per share for the quarter, topping the consensus estimate of ($8.10) by $126.33. On average, research analysts expect that Aptevo Therapeutics will post -15.84 earnings per share for the current year.

Hedge Funds Weigh In On Aptevo Therapeutics

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Birchview Capital LP acquired a new position in Aptevo Therapeutics Inc. (NASDAQ:APVO) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $30,000. Birchview Capital LP owned 1.32% of Aptevo Therapeutics as of its most recent filing with the SEC. 8.06% of the stock is currently owned by institutional investors and hedge funds.

About Aptevo Therapeutics

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.